多巴胺转运体PET显像剂<sup>11</sup>C-Altropane的研究进展

于江; 段玉清; 毕常芬; 李祎亮; 于江; 段玉清; 毕常芬; 李祎亮

doi:10.3760/cma.j.issn.1673-4114.2018.01.014

[1]

Wang J, Zuo CT, Jiang YP, et al. ¹⁸F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages[J]. J Neurol, 2007, 254(2):185-190. DOI:10.1007/s00415-006-0322-9.

[2]

Ma Y, Dhawan V, Mentis M, et al. Parametric mapping of[¹⁸F]FPCIT binding in early stage Parkinson's disease:a PET study[J]. Synapse, 2002, 45(2):125-133. DOI:10.1002/syn.10090.

[3]

许靖, 李肖红, 秦永德, 等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志, 2016, 40(5):338-344. DOI:10.3760/cma.j.issn.1673-4114. 2016.05.003.
Xu J, Li XH, Qin YD, et al. Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson's disease[J]. Int J Radiat Med Nucl Med, 2016, 40(5):338-344. doi: 10.3760/cma.j.issn.1673-4114.2016.05.003

[4]

Jankovic J. Parkinson's disease:clinical features and diagnosis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(4):368-376. DOI:10.1136/jnnp.2007.131045.

[5]

Morón JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter:evidence from knock-out mouse lines[J]. J Neurosci, 2002, 22(2):389-395.

[6]

Thobois S, Jahanshahi M, Pinto S, et al. PET and SPECT functional imaging studies in Parkinsonian syndromes:from the lesion to its consequences[J]. Neuroimage, 2004, 23(1):1-16. DOI:10.1016/j.neuroimage.2004.04.039.

[7]

李英华, 关锋, 代玉银, 等.正电子放射性分子显像剂诊断帕金森氏病的研究进展[J].核技术, 2012, 35(3):211-215.
Li YH, Guan F, Dai YY, et al. Positron radioactive molecular imaging agents for early diagnosis of Parkinson's disease[J]. Nucl Tech, 2012, 35(3):211-215.

[8]

Huang T, Wang H, Tang G, et al. The influence of residual nor-β-CFT in ¹¹C CFT injection on the Parkinson disease diagnosis:a ¹¹C CFT PET study[J]. Clin Nucl Med, 2012, 37(8):743-747. DOI:10.1097/RLU.0b013e31824c5fae.

[9]

Hung JC. Bringing new PET drugs to clinical practice-a regulatory perspective[J]. Theranostics, 2013, 3(11):885-893. DOI:10.7150/thno.5513.

[10]

Zhu L, Ploessl K, Kung HF. Chemistry. expanding the scope of fluorine tags for PET imaging[J]. Science, 2013, 342(6157):429-430. DOI:10.1126/science.1245011.

[11]

乔晋萍, 乔洪文, 武仙英, 等.多巴胺神经系统显像分子探针研究[J].生命的化学, 2014, 34(2):154-165. DOI:10.13488/j.smhx.20140204.
Qiao JP, Qiao HW, Wu XY, et al. Recent advances in PET tracers for imaging of the dopaminergic system[J]. Chem Life, 2014, 34(2):154-165. doi: 10.13488/j.smhx.20140204

[12]

甘红梅, 乔晋萍, 孔爱英, 等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志, 2010, 34(2):65-71. DOI:10.3760/cma.j.issn.1673-4114.2010.02.001.
Gan HM, Qiao JP, Kong AY, et al. The progress on researching method and metabolism of positron radiopharmaceutical[J]. Int J Radiat Med Nucl Med, 2010, 34(2):65-71. doi: 10.3760/cma.j.issn.1673-4114.2010.02.001

[13]

Quincoces G, Peñuelas I, Valero M, et al. Simple automated system for simultaneous production of ¹¹C-labeled tracers by solid supported methylation[J]. Appl Radiat Isot, 2006, 64(7):808-811. DOI:10.1016/j.apradiso.2006.03.001.

[14]

Elmaleh DR, Fischman AJ, Shoup TM, et al. Preparation and biological evaluation of iodine-125-IACFT:a selective SPECT agent for imaging dopamine transporter sites[J]. J Nucl Med, 1996, 37(7):1197-1202.

[15]

Fischman AJ, Bonab AA, Babich JW, et al.[¹¹C, ¹²⁷I] Altropane:a highly selective ligand for PET imaging of dopamine transporter sites[J]. Synapse, 2001, 39(4):332-342. DOI:10.1002/1098-2396(20010315)39:4<332::AID-SYN1017>3.0.CO;2-X.

[16]

Dutta AK, Zhang S, Kolhatkar R, et al. Dopamine transporter as target for drug development of cocaine dependence medications[J]. Eur J Pharmacol, 2003, 479(1/3):93-106. DOI:10.1016/j.ejphar.2003.08.060.

[17]

张锦明, 田嘉禾, 郭喆, 等.在线自动化制备多巴胺转运蛋白显像剂¹¹C-β-CFT[J].中华核医学杂志, 2005, 25(3):142-145. DOI:10.3760/cma.j.issn.2095-2848.2005.03.006.
Zhang JM, Tian JH, Guo Z, et al. Automated on-line preparation of ¹¹C-β-CFT, a dopamine transporter imaging agent[J]. Chin J Nucl Med, 2005, 25(3):142-145. doi: 10.3760/cma.j.issn.2095-2848.2005.03.006

[18]

Rinne JO, Bergman J, Ruottinen H, et al. Striatal uptake of a novel PET ligand, [¹⁸F]beta-CFT, is reduced in early Parkinson's disease[J]. Synapse, 1999, 31(2):119-124. DOI:10.1002/(SICI) 1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O.

[19]

Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo[¹²³I] β-CIT binding to dopamine transporters in healthy human subjects[J]. J Cereb Blood Flow Metab, 1994, 14(6):982-994. DOI:10.1038/jcbfm.1994.131.

[20]

Djaldetti R, Treves TA, Ziv I, et al. Use of a single[¹²³I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease[J]. Neurol Sci, 2009, 30(4):301-305. DOI:10.1007/s10072-009-0100-4.

[21]

Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT[J]. J Nucl Med, 1996, 37(7):1129-1133.

[22]

Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅰ. Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29(2):93-104. DOI:10.1002/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO;2-5.

[23]

Madras BK, Gracz LM, Meltzer PC, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: Ⅱ. Distritution to dopamine-rich region of primate brain[J]. Synapse, 1998, 29(2):105-115. DOI:10.1002/(SICI)1098-2396(199806)29:2<105:AID-SYN2>3.0.CO;2-B.

[24]

Madras BK, Gracz LM, Fahey MA, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅲ. Human dopamine transporter in postmortem normal and Parkinson's diseased brain[J]. Synapse, 1998, 29(2):116-127. DOI:10.1002/(SICI)1098-2396(199806)29:2<116:AID-SYN3>3.0.CO;2-A.

[25]

Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane:a selective ligand for dopamine transporters[J]. Synapse, 1998, 29(2):128-141. DOI:10.1002/(SICI)1098-2396(199806)29:2<128:AID-SYN4>3.0.CO;2-9.

[26]

Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using[¹¹C] altropane and[¹¹C] raclopride[J]. Biol Psychiatry, 2010, 68(10):964-970. DOI:10.1016/j.biopsych.2010.08.026.

[27]

Spencer TJ, Biederman J, Faraone SV, et al. Functional genomics of attention-deficit/hyperactivity disorder(ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects[J]. Biol Psychiatry, 2013, 74(2):84-89. DOI:10.1016/j.biopsych.2012.11.010.

[28]

Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an ¹¹C altropane positron emission tomography study[J/OL]. Alzheimers Res Ther, 2014, 6(5-8): 52[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245149. DOI: 10.1186/s13195-014-0052-7.

[29]

Rieckmann A, Gomperts SN, Johnson KA, et al. Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases[J/OL]. Neuroimage Clin, 2015, 8: 554-559[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484547. DOI: 10.1016/j.nicl.2015.06.001.

[30]

Rieckmann A, Hedden T, Younger AP, et al. Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity[J]. Hum Brain Mapp, 2016, 37(2):621-631. DOI:10.1002/hbm.23054.

[31]

Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system[J]. Curr Med Chem, 2006, 13(18):2139-2153. DOI:10.2174/092986706777935258.

[32]

李海峰, 张晓军, 张锦明, 等.多巴胺转运蛋白显像剂¹¹C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志, 2016, 40(3):218-224. DOI:10.3760/cma.j.issn.1673-4114. 2016.03.011.
Li HF, Zhang XJ, Zhang JM, et al. Review of the use of dopamine transporter imaging agent ¹¹C-β-CFT for diagnosing Parkinson disease[J]. Int J Radiat Med Nucl Med, 2016, 40(3):218-224. doi: 10.3760/cma.j.issn.1673-4114.2016.03.011